Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $52.55 USD
Change Today +1.29 / 2.52%
Volume 2.7M
PKI On Other Exchanges
As of 8:04 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

perkinelmer inc (PKI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/1/15 - $53.52
52 Week Low
10/15/14 - $38.96
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PERKINELMER INC (PKI)

perkinelmer inc (PKI) Related Businessweek News

No Related Businessweek News Found

perkinelmer inc (PKI) Details

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, and to accelerate the discovery and development of critical new therapies. It provides early detection for genetic disorders from pregnancy to early childhood, well as flat panel X-ray detectors and infectious disease testing for the diagnostics market; and a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. This segment’s research portfolio includes instrumentation for automation and detection solutions, and in vitro and in vivo imaging and analysis hardware and software; and a portfolio of consumable products, including drug discovery and research reagents. The Environmental Health segment provides products, services, and solutions to facilitate the creation of safer food and consumer products. It develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, soil, and food. This segment also provides analytical instrumentation for the industrial market, which includes the chemical, petrochemical, lubricant, polymer, electronics, pharmaceutical, and food and dietary supplement industries; and laboratory services. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.

7,700 Employees
Last Reported Date: 04/30/15
Founded in 1931

perkinelmer inc (PKI) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $1.0M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $492.3K
Senior Vice President and President of Enviro...
Total Annual Compensation: $400.0K
Senior Vice President and President of Human ...
Total Annual Compensation: $383.1K
Senior Vice President of Administration, Gene...
Total Annual Compensation: $410.4K
Compensation as of Fiscal Year 2014.

perkinelmer inc (PKI) Key Developments

PerkinElmer Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 29, 2015; Revised Earnings Guidance for Fiscal 201

PerkinElmer Inc. reported consolidated earnings results for the first quarter ended March 29, 2015. The company reported GAAP earnings per diluted share from continuing operations of $0.36, as compared to $0.31 per diluted share in the first quarter of 2014. GAAP revenue in the first quarter of 2015 was $526.9 million, as compared to $530.6 million in the first quarter of 2014. GAAP operating income from continuing operations for the first quarter of 2015 was $57.4 million, as compared to $51.8 million in the first quarter of 2014. Adjusted earnings per share was $0.50, as compared to $0.47 in the first quarter of 2014. Adjusted revenue for the quarter was $527.2 million, as compared to $532.1 million in the first quarter of 2014. Adjusted operating income for the first quarter of 2015 was $82.8 million, as compared to $79.4 million for the same period a year ago. For the first quarter of 2015, GAAP operating cash flow from continuing operations, after taking into account approximately $24.0 million of voluntary pension funding, was $37.6 million, as compared to $68.1 million in the comparable period of 2014. Income from continuing operations, before income taxes was $47,960,000 against $40,473,000 a year ago. Capital expenditures was $4,479,000 against $6,020,000 a year ago. For the full year 2015, the company now forecasts GAAP earnings per share from continuing operations in the range of $2.06 to $2.12 and updates on a non-GAAP basis, which is expected to include the adjustments, adjusted earnings per share of $2.54 to $2.60 which now represents 12%-15% constant currency adjusted earnings per share growth as compared to the company's prior guidance of 11%-13%. The guidance now assumes that the stronger U.S. dollar will negatively impact adjusted earnings per share for 2015 by a total of $0.23 as compared to the company’s original guidance of $0.15.

PerkinElmer Inc. Declares Quarterly Dividend, Payable on August 10, 2015

The Board of Directors of PerkinElmer Inc. declared a regular quarterly dividend of $0.07 per share of common stock on April 27, 2015. This dividend is payable on August 10, 2015 to all shareholders of record at the close of business on July 17, 2015.

PerkinElmer, Inc Launches its New Quantulus GCT and Tri-Carb 4810TR, 4910TR, and 5110TR Liquid Scintillation Counters

PerkinElmer Inc. has launched its new Quantulus GCT and Tri-Carb 4810TR, 4910TR, and 5110TR liquid scintillation counters, or LSCs. These modernized benchtop systems, which are among the most sensitive available in the marketplace, measure low levels of radioactivity and perform advanced particle discrimination. They also feature reduced counting times for detecting alpha, beta and gamma radioactivity. Pharmaceutical and biopharmaceutical lab professionals can leverage PerkinElmer's LSCs for their high sensitivity and ability to detect and measure low levels of radioactivity. Environmental scientists can rely on the LSCs to test the safety of air, water, soil and crops. These systems also help monitor laboratories to ensure the safety of personnel using radiation during their research. The Quantulus GCT liquid scintillation counter is a benchtop instrument that identifies and measures very low concentrations of man-made, cosmogenic and other natural radionuclides. It is suited for environmental monitoring and contamination control, which require detection of ultra low-level alpha and beta radioactivity. The Tri-Carb family of LSCs are computer-controlled benchtop instruments that perform particle discrimination with reduced counting times for detecting very small amounts of alpha, beta and gamma radioactivity. These highly sensitive LSCs can meet the requirements of demanding academic, pharmaceutical, including ADME-Tox, environmental, and nuclear power research applications.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PKI:US $52.55 USD +1.29

PKI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Getinge AB kr203.20 SEK -1.60
IDEXX Laboratories Inc $132.93 USD +7.56
MEDNAX Inc $71.60 USD +0.82
QIAGEN NV €21.08 EUR -0.209
Teleflex Inc $122.61 USD -0.35
View Industry Companies

Industry Analysis


Industry Average

Valuation PKI Industry Range
Price/Earnings 35.9x
Price/Sales 2.7x
Price/Book 2.9x
Price/Cash Flow 36.3x
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERKINELMER INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at